Lack of pharmacokinetic interactions between argatroban and warfarin

American Journal of Health-System Pharmacy

Volumn 59, Issue 21, 2002, Pages 2078-2083

  Brown, Philip M ^a   Hursting, Marcie J ^a  

^a Clinical Science Consulting   (United States)

Author keywords

Anticoagulants; Argatroban; Blood levels; Drug interactions; Excretion; Pharmacokinetics; Prothrombin time; Rate constants; Toxicity; Warfarin

Indexed keywords

ARGATROBAN; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG INFUSION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL;

EID: 0036830650     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.21.2078     Document Type: Article

References (25)

1. Swan SK, St. Peter JV, Lambrecht LJ et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy. 2000; 20:756-70.
2. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000; 20:318-29.
3. Argatroban Package Insert. Philadelphia: GlaxoSmithKline; 2002 Apr.
4. Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001; 103:1838-43.
5. Lewis BE, Matthai WH, Cohen M et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet Cardiovasc Interv. In press.
6. Jang I-K, Brown DFM, Giugliao RP et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial Infarction with Novastan and TPA (MINT) trial. J Am Coll Cardiol. 1999; 33:1879-85.
7. Vermeer F, Vahanian A, Fels P et al. Argatroban and alteplase in patients with acute myocardial infarction: The ARGAMI study. J Thromb Thrombolysis. 2000; 10: 233-40.
8. Gold HK, Torres FW, Garabedian HD et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol. 1993; 21:1039-47.
9. Matsuo T, Kario K, Matsuda S et al. Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: A multicenter clinical trial of argatroban. J Thromb Thrombolysis. 1995; 2:131-6.
10. Herrman J-P, Suryapranata H, den Heijer P et al. Argatroban during percutaneous transluminal coronary angioplasty: Results of a dose-verification study. J Thromb Thrombolysis. 1996; 3:367-75.
11. Kobayashi S, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost. 1997; 23:531-4.
12. Matsuo T, Chikahira Y, Yamada T et al. Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis. Thromb Res. 1988; 52:165-71.
13. Izawa O, Katsuki M, Komatsu T et al. Pharmacokinetic studies of argatroban (MD-805) in human: Concentrations of argatroban and its metabolites in plasma, urine and feces during and after drip intravenous infusion. Jpn Pharmacol Ther. 1986; 14:251-63.
14. Ahsan A, Ahmad S, Iqbal O et al. Comparative studies on the biochemical and pharmacological properties of a major metabolite of argatroban (M1): Potential clinical implications. Thromb Haemost. 1997; 78(suppl 2):370. Abstract.
15. Tran JQ, DiCicco RA, Sheth SB et al. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol. 1999; 39:513-9.
16. Clark RJ, Mayo G, Fitzgerald GA et al. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation. 1991; 83:1510-8.
17. Inglis AL, Sheth SB, Hursting MJ et al. Lack of interaction between argatroban, a direct thrombin inhibitor, and three frequently prescribed medications, acetaminophen, lidocaine and digoxin. Am J Health-Syst Pharm. 2002; 59:1258-66.
18. Lewis BE, Wallis DE, Leya F et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Int Med. In press.
19. Coumadin Package Insert. Wilmington, DE: DuPont Pharma; 1996 Aug.
20. American Society of Health-System Pharmacists. ASHP therapeutic position statement on the use of International Normalized Ratio system to monitor oral anticoagulant therapy. Am J Health-Syst Pharm. 1995; 52:529-31.
21. Stirling Y, Howarth DJ, Stockley R et al. Comparison of the bioavailabilities and anticoagulant activities of two warfarin formulations. Br J Haematol. 1982; 51:37-46.
22. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15:657-80 .
23. Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet. 1986; 11:483-504.
24. Hursting MJ, Zehnder JL, Joffrion JL et al. The International Normalized Ratio during concurrent warfarin and argatroban anticoagulation: Differential contributions of each agent and effects of the choice of thromboplastin used. Clin Chem. 1999; 45:409-12.
25. Sheth SB, DiCicco RA, Hursting MJ et al. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost. 2001; 85:435-40.